卡前列素氨丁三醇注射液与缩宫素在产后出血的临床预防效果分析(1)
[摘要] 目的 研究卡前列素氨丁三醇注射液联合缩宫素预防产后出血的临床疗效。方法 随机选取该院96例2015年1月—2016年2月收治的高危产妇，采用随机数字法分为对照组和观察组。观察组48例，娩出后给予卡前列素氨丁三醇注射液皮下注射联合缩宫素静脉滴注；对照组48例，仅注射缩宫素。观察两组患者产后出血量、出血率及不良反应。结果 ①观察组24 h内出血量明显低于对照组，出血例数少于对照组，出血率为2.1%，显著低于对照组16.7%，P<0.05；②对照组和观察组均有数例患者发生血压升高、恶心、呕吐、心悸等不良反应，不良反应发生率分别为16.7%、10.4%，对照组略高于观察组，但差异无统计学意义，P>0.05。结论 卡前列素氨丁三醇注射液联合缩宫素预防产后出血效果较好，出血量、出血率均有显著改降低，不良反应未见增加，安全可靠。
[关键词] 卡前列素氨丁三醇注射液；缩宫素；产后出血
[中图分类号] R714 [文献标识码] A [文章编号] 1674-0742(2016)09(c)-0140-03
[Abstract] Objective To studythe clinical effect observation of carboprost tromethamine injection combined with oxytocin in preventing postpartumhemorrhage. Methods To randomly select 96 patients with postpartumhemorrhage admitted in January 2015 to February 2016，and devide into control group and study group by random number method. The study group which includes 48 patients is given carboprost tromethamine injection combined with oxytocin； the control group which includes 48 patients is only given oxytocin； bleeding rate and adverse reactions were observed in the two groups. Results ①The amount of 24h bleeding in the observation group was significantly lower than that of the control group， and the number of bleeding cases were less than the control group， the bleeding rate was 2.1%， which was significantly lower than that of the control group 16.7%， P < 0.05. ②The incidence of adverse reactions in the control group and the observation group were 16.7% and 10.4% respectively， while the control group was slightly higher than the observation group， but no significant difference was observed， P > 0.05. Conclusion The clinical effect observation of carboprost tromethamine injection combined with oxytocin in preventing postpartumhemorrhage is apparent， with less bleeding and lower bleeding rates and adverse effects， it is safe and reliable.
[Key words] Carboprost tromethamine injection； Oxytocin； Postpartum hemorrhage
产后出血是产后常见的并发症，是引起孕产妇死亡最常见原因，居我国孕产妇死亡原因的首位[1]。控制产后出血才能降低产后死亡率。卡前列素氨丁三醇是前列腺类物质，具有使子宫平滑肌收缩加强、促进血管关闭的作用[2]。缩宫素是机体本来就存在的激素，可刺激子宫上段收缩，广泛用于治疗及预防各种出血性疾病。研究发现[3]，卡前列素氨丁三醇注射液联合缩宫素在产后出血的预防上有一定优势。因此笔者针对2015年1月—2016年2月收治的96例高危妊娠产妇开展了临床研究，现报道如下。
1 资料与方法
1.1 一般资料
本实验研究对象为随机选取入该院治疗的96例高危妊娠产妇。其中观察组48例，平均年龄(31.2±5.5)岁；对照组48例，患者年龄20～38岁，平均年龄(32.3±5.1)岁。两组患者基本资料差异无统计学意义，P>0.05。病例纳入标准：①有高危因素的产妇，如巨大儿、瘢痕子宫、前置胎盘等；②签署知情同意书。病例排除标准[4-5]：①严重认知障碍；②合并高血压、心脏病、糖尿病等疾病；③合并凝血功能障碍；④存在已知药物禁忌症。
1.2 方法
随机选取96例高危妊娠产妇，分为对照组和观察组。观察组48例，娩出后给予0.25 mg卡前列素氨丁三醇注射液(批准文号：国药准字H20094183)肌内注射，并联合20 U缩宫素(批准文号：国药准字H62020713)静脉滴注；对照组48例，仅注射缩宫素，剂量同观察组。观察两组患者产后24 h出血情况及不良反应。 (张静)
[关键词] 卡前列素氨丁三醇注射液；缩宫素；产后出血
[中图分类号] R714 [文献标识码] A [文章编号] 1674-0742(2016)09(c)-0140-03
[Abstract] Objective To studythe clinical effect observation of carboprost tromethamine injection combined with oxytocin in preventing postpartumhemorrhage. Methods To randomly select 96 patients with postpartumhemorrhage admitted in January 2015 to February 2016，and devide into control group and study group by random number method. The study group which includes 48 patients is given carboprost tromethamine injection combined with oxytocin； the control group which includes 48 patients is only given oxytocin； bleeding rate and adverse reactions were observed in the two groups. Results ①The amount of 24h bleeding in the observation group was significantly lower than that of the control group， and the number of bleeding cases were less than the control group， the bleeding rate was 2.1%， which was significantly lower than that of the control group 16.7%， P < 0.05. ②The incidence of adverse reactions in the control group and the observation group were 16.7% and 10.4% respectively， while the control group was slightly higher than the observation group， but no significant difference was observed， P > 0.05. Conclusion The clinical effect observation of carboprost tromethamine injection combined with oxytocin in preventing postpartumhemorrhage is apparent， with less bleeding and lower bleeding rates and adverse effects， it is safe and reliable.
[Key words] Carboprost tromethamine injection； Oxytocin； Postpartum hemorrhage
产后出血是产后常见的并发症，是引起孕产妇死亡最常见原因，居我国孕产妇死亡原因的首位[1]。控制产后出血才能降低产后死亡率。卡前列素氨丁三醇是前列腺类物质，具有使子宫平滑肌收缩加强、促进血管关闭的作用[2]。缩宫素是机体本来就存在的激素，可刺激子宫上段收缩，广泛用于治疗及预防各种出血性疾病。研究发现[3]，卡前列素氨丁三醇注射液联合缩宫素在产后出血的预防上有一定优势。因此笔者针对2015年1月—2016年2月收治的96例高危妊娠产妇开展了临床研究，现报道如下。
1 资料与方法
1.1 一般资料
本实验研究对象为随机选取入该院治疗的96例高危妊娠产妇。其中观察组48例，平均年龄(31.2±5.5)岁；对照组48例，患者年龄20～38岁，平均年龄(32.3±5.1)岁。两组患者基本资料差异无统计学意义，P>0.05。病例纳入标准：①有高危因素的产妇，如巨大儿、瘢痕子宫、前置胎盘等；②签署知情同意书。病例排除标准[4-5]：①严重认知障碍；②合并高血压、心脏病、糖尿病等疾病；③合并凝血功能障碍；④存在已知药物禁忌症。
1.2 方法
随机选取96例高危妊娠产妇，分为对照组和观察组。观察组48例，娩出后给予0.25 mg卡前列素氨丁三醇注射液(批准文号：国药准字H20094183)肌内注射，并联合20 U缩宫素(批准文号：国药准字H62020713)静脉滴注；对照组48例，仅注射缩宫素，剂量同观察组。观察两组患者产后24 h出血情况及不良反应。 (张静)